Dr. Reddy's Labs Bags Health Canada Nod for Ozempic Generic, OneSource to Scale Supply
New Delhi: OneSource Specialty Pharma Limited has announced that its partner Dr. Reddy's Laboratories Ltd. has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.
The partnership is designed to ensure reliable and scalable commercial supply from OneSource’s USFDA approved flagship manufacturing facility in Bengaluru.
Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: “We are pleased to announce that our partner Dr. Reddy’s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy’s expertise in peptide development with OneSource’s CDMO capabilities.”
OneSource Specialty Pharma Limited is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information,
